1. Inciardi JA, Surratt HL, Kurtz SP, Burke JJ. The diversion of prescription drugs by health care workers in Cincinnati, Ohio. Subst Use Misuse. 2006;41:1–10. [PubMed]
2. Inciardi JA, Goode JL. OxyContin and prescription drug abuse. Consumers Res. 2003;86(7):17–21.
3. Meier B, Killer Pain. A “Wonder” Drug's Trail of Addiction and Death. Emmaus, PA: Rodale Press; 2003.
4. Nagel LM, Good PM. DEA—Industry Communicator Oxycontin Special. Washington, DC: U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control; 2001.
5. National Institute on Drug Abuse. Prescription Drugs: Abuse and Addiction. Bethesda, MD: NIDA Research Report; 2001. NIH publication 01-4881.
6. Thompson CA. Prescription drug misuse highlighted as national problem. Am J Health Syst Pharm. 2001;58(956):60. [PubMed] 7. Zacny J, Bigelow G, Compton P, et al. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug Alcohol Depend. 2003;69(3):215–32. [PubMed] 8. National Drug Satety Network. Prescription drug abuse rivals illicit drug abuse. Some see double standard in law enforcement. News Briefs—Drug use Trends. [December 6, 2006]. Available at: http://www.ndsn.org/oct96/prescrip.html.
9. U.S. General Accounting Office. Oxycontin Abuse and Diversion and Efforts to Address the Problem [Report to Congressional Requesters, #GAO-04-110] Washington, DC: U.S. Government Printing Office; 2003. Dec,
10. Weathermon RA. Controlled substances diversion: Who attempts it and how. US Pharm. 1999;24(12):32–47.
11. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manage. 2004;28(2):176–88. [PubMed] 12. Forgione DA, Neuenschwander P, Vermeer TE. Diversion of prescription drugs to the black market: What the states are doing to curb the tide. J Health Care Finance. 2001;27(4):65–78. [PubMed] 13. Chandra A, Ozturk A. Health professionals beware of prescription pain medication abuse and diversion. Hosp Top. 2004;82(4):34–7. [PubMed]
14. Inciardi JA. Prescription Drug Diversion. Paper presented at: Opioid Risk Management Conference; March 29, 2005; Boston, MA.
15. Inciardi JA, Surratt HL. Research Issues and Experiences in Studying Prescription Drug Diversion. Paper presented at: College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; April 19-20, 2005; North Bethesda, MD.
16. Valdez A, Cepeda A, Kaplan CD, Yin Z. The legal importation of prescription drugs into the United States from Mexico: A study of customs declaration forms. Subst Use Misuse. 1998;33(12):2485–97. [PubMed]
17. Valdez A, Sifaneck SJ. Drug tourists and drug policy on the U.S.–Mexican border: An ethnographic investigation of the acquisition of prescription drugs. J Drug Issues. 1997;27(4):879–97.
18. Haddox JD. The Standards for Risk Management Plans for High Abuse Potential Medications. Paper presented at: College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; April 19-20, 2005; North Bethesda, MD.
19. Leiderman DB. Prescription Drugs and the Risks of Abuse, Addiction, and Overdose: Regulatory Challenges; College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; 2005; North Bethesda, MD.
20. CASA (The National Center on Addiction and Substance Abuse at Columbia University) “You've Got Drugs!”: Prescription Drug Pushers on the Internet [a CASA White Paper] New York: Author; 2004. Feb,
21. Volkow ND. Priorities in Prescription Drug Abuse Research; Paper presented at: College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; April 19-20, 2005; North Bethesda, MD.
22. Bergman U, Dahl-Puustinen ML. Use of prescription forgeries in a drug abuse surveillance network. Eur J Clin Pharmacol. 1989;36:621–3. [PubMed]
23. Blumenschein K. Prescription drug diversion: Fraudulent tactics utilized in the community pharmacy. Am J Pharm Educ. 1997;61:184–8.
24. Borsack S. Hospital drug diversion: The verdict is in. Health Matrix. 1986-1987;4(4):27–31. [PubMed] 25. Cooper JR, Czechowicz DJ, Petersen RC, Molinari SP. Prescription drug diversion control and medical practice. J Am Med Assoc. 1992;268(10):1306–10. [PubMed] 26. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse. 2004;39(7):1095–116. [PubMed] 27. Simoni-Wastila L, Tompkins C. Balancing diversion control and medical necessity: The case of prescription drugs with abuse potential. Subst Use Misuse. 2001;36(9&10):1275–96. [PubMed] 28. Wilford BB, Finch J, Czechowicz DJ, Warren D. An overview of prescription drug misuse and abuse: Defining the problem and seeking solutions. J Law Med Ethics. 1994;22(3):197–203. [PubMed]
29. Adams EH. Risk Management Action Plans for Opioids Now and in the Future. Paper presented at: College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; April 19-20, 2005; North Bethesda, MD.
30. Cone EJ. Ephemeral Profiles of Prescription Drug Tampering: Evolving Pseudoscience on the Internet. Paper presented at: College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; April 19-20, 2005; North Bethesda, MD.
31. McCormick CG. Regulatory Challenges for New Formulations in Today's Environment. Paper presented at: College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; April 19-20, 2005; North Bethesda, MD.
32. Sapienza FL. Abuse Resistant Formulations and the Controlled Substances Act. Paper presented at: College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; April 19-20, 2005; North Bethesda, MD.
33. Schuster CR. History and Current Perspectives on the Use of Drug Formulations to Decrease the Abuse of Prescription Drugs. Paper presented at: College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; April 19-20, 2005; North Bethesda, MD.
34. Smith MY. Measuring Rates of Nonmedical Use—Dimensions and Denominators; Paper presented at: College on Problems of Drug Dependence: Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference; April 19-20; North Bethesda, MD. 2005.
35. U.S. Drug Enforcement Administration. DEA Unveils International Toll-Free Hotline to Report Illegal Prescription Drug Sales and Rogue Pharmacies Operating on the Internet. [January 25, 2005]. Available at: http://www.usdoj.gov/dea/pubs/pressrel/pr121504.html. 36. Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of OxyContin® and other opioid analgesics in the United States: 2002–2004. Pain. 2005;6(10):662–72. [PubMed]
37. Inciardi JA, Surratt HL. Trends in the Diversion of Prescription Drugs; Paper presented at: CPDD 68th Annual Scientific Meeting; June 17-22, 2006; Scottsdale, AZ.
38. Leap WL. Word's Out: Gay Men's English. Minneapolis, MN: University of Minnesota Press; 1996.
39. Miles MB, Huberman M. Qualitative Data Analysis. Thousand Oaks, CA: Sage Publications; 1994.
40. Charmaz K. Grounded theory: Objectivist and constructivist methods. In: Denzin NK, Lincoln YS, editors. Handbook of Qualitative Research. 2nd. Thousand Oaks, CA: Sage Publications; 2000. pp. 509–35.
41. Glaser BG, Strauss AL. Discovery of Grounded Theory: Strategies for Qualitative Research. Hawthorne, NY: Walter de Guyter; 1967.
42. Kurtz SP. Epidemiologic Trends in Drug Abuse, Advance Report: Prescription Drug Abuse Community Epidemiology Work Group, June 2004. Vol. 2004. Rockville, MD: The Institute; Nov, 2004. Prescription drug abuse among ecstasy users in Miami: Qualitative research findings; pp. 43–7. NIH Publication No 04-5363A.
43. Kurtz SP, Inciardi JA, Surratt HL, Cottler L. Prescription drug abuse among ecstasy users in Miami. J Addict Dis. 2005;24(4):1–16. [PubMed] 44. Griffith J. A study of illicit amphetamine drug traffic in Oklahoma City. Am J Psychiatry. 1966;123:560–9. [PubMed] 45. Kramer JC, Fischman VS, Littlefield DC. Amphetamine abuse. Pattern and effects of high doses taken intravenously. J Am Med Assoc. 1967;201:305–9. [PubMed]
46. Chambers CD, Brill L, Inciardi JA. Barbiturate use, misuse, and abuse. J Drug Issues. 1972;2:15–20.
47. U.S. General Accounting Office. Retail Diversion of Legal Drugs—A Major Problem with No Easy Solution [Report to the Congress by the Comptroller General of the United States: DEA Report #GGD-78-22 Issued March 10, 1978] Washington, DC: U.S. Government Printing Office; 1978.
48. Inciardi JA, Petersen DM, Chambers CD. Methaqualone abuse patterns, diversion paths and adverse reactions. J Fla Med Assoc. 1974;61:279–83. [PubMed]
49. U.S. Congress. Legislative Hearings on the Meth-aqualone Control Act of 1973, S 1252. Washington, DC: U.S. Government Printing Office; 1973. Senate and Subcommittee to Investigate Juvenile Delinquency of the Committee on the Judiciary.
50. Chambers CD, Inciardi JA, Stephens RC. A critical review of pentazocine abuse. HSMHA Health Rep. 1971;86(7):627–36. [PMC free article] [PubMed] 51. Goldman FR, Thistel CI. Diversion of methadone: Illicit methadone use among applicants to two metropolitan drug abuse programs. Int J Addict. 1978;13(6):855–62. [PubMed]
52. Inciardi JA. NIDA Services Research Monograph, DHEW Pub. No. (ADM) 77-488. Rockville, MD: National Institute on Drug Abuse; 1977. Methadone Diversion: Experience and Issues.
53. Resnick RB. Problems of methadone diversion and implications for control. Int J Addict. 1977;12(7):803–6. [PubMed]
54. Chambers CD, Inciardi JA. An Assessment of Drug Use in the General Population. Albany, NY: New York State Narcotic Addiction Control Commission; 1971.
55. Chambers CD, Brill L. Methadone: Experiences and Issues. New York City: Behavioral Publications; 1973.
56. Weppner RS, Stephens RC. The illicit use and diversion of methadone on the street as related by hospitalized addicts. J Drug Issues. 1973;3(Winter):111–5.
57. Inciardi JA. Careers in Crime. Chicago, IL: Rand McNally College Publishing Company; 1975.
58. Bureau of Justice Statistics. Criminal Victimization in the United States, 2004. Washington, DC: Author; 2005.
59. Associated Press. Miami Man Gets Prison Time for Illegally Selling Pharmaceuticals. [May 31, 2005]; Available at: LexisNexis Academic database.
60. Breister P. Area authorities on alert after home invasions. Reporter. 2005;04A
61. Gedan B. Despite 2 arrests, break-ins still soar. Boston Globe. 2004 September 26;12
63. McDonald M. Suspect held in rash of burglaries. Boston Globe. 2004 December 5;4
65. Weisel DL. Burglary of Single-Family Houses [Problem-Oriented Guides for Police Series, No 18] Washington, DC: U.S. Department of Justice: Office of Community Oriented Policing Services; 2004.
66. Wellsmith M, Burrell A. The influence of purchase price and ownership levels on theft targets: The example of domestic burglary. Br J Criminol. 2005;45(5):741–64.
67. Sutton M. Supply by theft: Does the market for second-hand goods play a role in keeping crime figures high? Br J Criminol. 1995;35(Summer):400–16.
70. Joranson DE, Gilson AM. Drug crime is a source of abused pain medications in the United States. J Pain Symptom Manage. 2005;30(4):299–301. [PubMed]
71. Jesdanun A. Study: Few Americans Buy Drugs Online. New York: The Associated Press; [October 10, 2004]. Available at: LexisNexis Academic database.
72. Bogart JG, Stevens SJ, Hill RJ, Estrada BD. Criminally involved drug-using mothers: The need for system change. Prison J. 2005;85(1):65–82.
73. Logan TK, Leukefeld CG. Sexual and drug use behaviors among female crack users: A multi-site sample. Drug Alcohol Depend. 2000;58(3):237–45. [PubMed]
74. Nyamathi AM, Stein JA, Bayley LJ. Predictors of mental distress and poor physical health among homeless women. Psychol Health. 2000;15(4):483–500.
75. Roiser JP, Sahakian BJ. Relationship between ecstasy use and depression a study controlling poly-drug use. Psychopharmacology. 2004;173:411–7. [PMC free article] [PubMed] 76. Boyd CJ, McCabe SE, d'Arcy H. Ecstasy use among college undergraduates: Gender, race and sexual identity. J Subst Abuse Treat. 2003;24:209–15. [PubMed]
77. Associated Press. AIDS drugs surface on black market. Vol. 1. New York Times; Dec 25, 1995. p. 43.
78. Flaherty MP, Gaul GM. Florida Medicaid fraud costs millions, report says. Washington Post. 2003 December 19; Financial:E03.
79. LaPadula P. Four arrested in Miami AIDS drug scheme: Defendants accused of selling drugs on the black market. Express Gay News. 2005
80. Crumplin G. EU reimporting drugs meant for Africa is only part of story. BMJ. 2003;326(7383):285. [PMC free article] [PubMed]
81. Medicines Australia. The fight against HIV/AIDS. Med Health. 2002;1(12):1.
82. Klein A. Authorities shut down stolen medicines market with arrest of 17. Record. 2004 September 10;
83. Dorschner J. Four arrested in AIDS drug scam. Miami Herald. 2005 December 2;1C
84. Glasgow K. The new dealers: They're poor, Black, and HIV-positive. Their product? The AIDS medications intended to cure them. Miami New Times. 1999 October 21;
87. Windham C. Cracking down on illicit use of AIDS drugs. Wall Street Journal. 2004 January 19;B1
88. Bamberger JD, Unick J, Klein P, et al. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health. 2000;90(5):699–701. [PubMed]
89. Whitney N, Glazier R. Factors affecting medication adherence among the homeless: A qualitative study of patients' perspectives. Univ Toronto Med J. 2004;82(1):6–9.
90. Dorschner J. Activists: HIV care scam uses homeless. Miami Herald. 2005 June 30;1A